Multidimensional study on mitochondrial dysfunction in pulmonary hypertension.

Area of Science:

• Cardiovascular Research
• Mitochondrial Biology
• Pulmonary Medicine

Background:

• Pulmonary hypertension (PH) involves hemodynamic abnormalities and vascular remodeling, leading to right ventricular hypertrophy and heart failure.
• While vasodilation therapies exist, they are limited in reversing vascular remodeling, highlighting the need for novel treatment strategies.
• Mitochondrial dysfunction is increasingly recognized as a central pathological mechanism in PH.

Purpose of the Study:

• To systematically review the molecular mechanisms of mitochondrial dysfunction in PH pathogenesis.
• To explore recent advancements in targeting mitochondrial dysfunction for PH treatment.
• To provide a comprehensive understanding of mitochondrial dysfunction's role in PH for developing new therapies.

Main Methods:

• Systematic review of literature on mitochondrial dysfunction in pulmonary hypertension.
• Analysis of multi-channel pathogenic mechanisms including mtDNA damage, ETC dysfunction, and protein homeostasis.
• Summary of recent research on therapeutic interventions targeting mitochondrial dysfunction.

Main Results:

• Mitochondrial dysfunction, including mtDNA damage, ETC defects, and impaired biogenesis, is a key factor in PH.
• Endothelial cell dysfunction and impaired metabolism are closely linked to PH, with mitochondria playing a crucial role.
• Existing therapies for PH do not effectively reverse vascular remodeling, underscoring the potential of mitochondrial-targeted treatments.

Conclusions:

• Mitochondrial dysfunction is a cornerstone in the pathogenesis of pulmonary hypertension.
• Targeting mitochondrial dysfunction presents a promising therapeutic strategy for PH, potentially reversing vascular remodeling.
• Further research into molecular mechanisms and therapeutic interventions is crucial for advancing PH treatment.